Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | KMO | O15229 | 2/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.35 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL810938 | 0.83 | CCR1 (0.48) | GRM5KMOIDO1TGFBR1 | |
| SCHEMBL31484870 | 0.83 | CCR1 (0.48) | GRM5KMOIDO1TGFBR1 | |
| SCHEMBL25118560 | 0.83 | IDO1 (0.55) | GRM5KMOIDO1MAPKAPK2NISCH | |
| SCHEMBL19248539 | 0.81 | CCR1 (0.61) | GRM5 | |
| SCHEMBL5934924 | 0.80 | ASIC3 (0.59) | GRM5KMOCTDSP1ASIC3TGFBR1 | |
| SCHEMBL20469167 | 0.79 | ASIC3 (0.40) | ASIC3TGFBR1 | |
| SCHEMBL31168033 | 0.79 | IDO1 (0.39) | GRM5KMOIDO1TGFBR1 | |
| SCHEMBL15624430 | 0.79 | CCR1 (0.41) | GRM5KMOTDP1 | |
| SCHEMBL28731089 | 0.78 | ASIC3 (0.57) | GRM5KMOCTDSP1ASIC3TGFBR1 | |
| SCHEMBL19072769 | 0.78 | TDP1 (0.43) | KMOTDP1IDO1TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9859511-B2 | Organoiridium complex for organic electroluminescent elements | TANAKA KIKINZOKU KOGYO K.K. (JP) | 2018-01-02 | — | — | US | disclosed |
| US-20170237021-A1 | ORGANIC IRIDIUM COMPLEX FOR ORGANIC ELECTROLUMINESCENT ELEMENTS | TANAKA KIKINZOKU KOGYO K.K. (JP) | 2017-08-17 | — | — | US | disclosed |
| US-20170237021-A1 | ORGANIC IRIDIUM COMPLEX FOR ORGANIC ELECTROLUMINESCENT ELEMENTS | TANAKA KIKINZOKU KOGYO K.K. (JP) | 2017-08-17 | — | — | US | disclosed |
| EP-3187503-A1 | ORGANIC IRIDIUM COMPLEX FOR ORGANIC ELECTROLUMINESCENT ELEMENTS | Tanaka Kikinzoku Kogyo K.K. (JP) | 2017-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170237021-A1 | ORGANIC IRIDIUM COMPLEX FOR ORGANIC ELECTROLUMINESCENT ELEMENTS | L1CAM, ETFA, TTI2 | GRM5 3368/4885NOTUM 1605/4885KMO 2882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.